(1)Women who are pregnant and/or lactating; or women who intend to conceive within a year;
(2)History of allergies to enalapril, folic acid or other components of the compound drug;
(3)History of adverse reactions or intolerance to enalapril or other ACE inhibitors, or drugs or supplements containing folic acid;
(4)Diagnosis or suspicion of secondary hypertension;
(5)Known serious medical conditions, including: Cardiovascular: patients with clinically diagnosed cardiac dysfunction (NYHA class III and above), hypertrophic obstructive cardiomyopathy, clinically significant valvular heart disease, acute coronary syndrome within the last 3 months, or percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG); or abnormal pre-enrollment ECG test results with clinically significant arrhythmias (atrial flutter, atrial fibrillation, grade II-III atrioventricular block, etc.); Digestive: a previous diagnosis of various types of viral hepatitis that are still in the active phase; abnormal pre-enrollment liver function test results (ALT, AST, GGT, TBIL, or DBIL 3 times higher than normal, ALB = 30g/L); gastrectomy and/or gastrojejunostomy; gastrointestinal dysfunction; Urinary: pre-enrollment serum creatinine greater than 200umol/L; clinical diagnosis of renal artery stenosis, isolated kidney, kidney transplantation and/or other diseases; Endocrine: type 1 diabetes or uncontrolled type 2 diabetes (fasting blood glucose above 11.1 mmol/L at pre-enrollment); previous diagnosis of hyperthyroidism and failure to correct; Respiratory: pulmonary heart disease; chronic obstructive pulmonary disease; Neuropsychiatric: recent transient ischemic attack or stroke (within the last 3 months); peripheral or severe autonomic dysfunction; mental or nervous system dysfunction, inability to express desire; known drug or alcohol dependence; Malignancy, malnutrition, hematopoietic disorders and other serious diseases.
(6)Significant signs of abnormalities as seen in laboratory tests or physical characteristics, which, at the discretion of the investigators, indicates that the patient is experiencing a serious illness or, may affect the observation and evaluation of the drug's efficacy or adverse events, or renders the patient unsuitable for participating in this study;
(7)Patients currently taking folate, B12, or B6, or any compounds containing them, who express an inability or a refusal to stop usage;
(8)Regular usage of folic acid supplements or compounds containing folic acid in the past 3 months;
(9)Participation in a clinical trial for a drug that has not yet been officially approved for marketing within one month prior to the first visit.

NCT03472508_exc_T1
Person
Women
NCT03472508_exc_T2
Condition
pregnant
NCT03472508_exc_T3
Observation
lactating
NCT03472508_exc_T4
Person
women
NCT03472508_exc_T5
Observation
intend to conceive
NCT03472508_exc_T6
Temporal
within a year
NCT03472508_exc_T7
Scope
women who intend to conceive within a year
NCT03472508_exc_T8
Scope
Women who are pregnant and/or lactating
NCT03472508_exc_T9
Observation
History
NCT03472508_exc_T10
Condition
allergies
NCT03472508_exc_T11
Drug
enalapril
NCT03472508_exc_T12
Drug
folic acid
NCT03472508_exc_T13
Drug
components of the compound drug
NCT03472508_exc_T14
Scope
enalapril, folic acid or other components of the compound drug
NCT03472508_exc_T15
Observation
History
NCT03472508_exc_T16
Condition
adverse reactions
NCT03472508_exc_T17
Condition
intolerance
NCT03472508_exc_T18
Drug
enalapril
NCT03472508_exc_T19
Qualifier
other
NCT03472508_exc_T20
Drug
ACE inhibitors
NCT03472508_exc_T21
Drug
folic acid
NCT03472508_exc_T22
Scope
adverse reactions or intolerance
NCT03472508_exc_T23
Scope
enalapril or other ACE inhibitors, or drugs or supplements containing folic acid
NCT03472508_exc_T24
Condition
secondary hypertension
NCT03472508_exc_T25
Mood
suspicion
NCT03472508_exc_T26
Mood
Diagnosis
NCT03472508_exc_T27
Scope
Diagnosis or suspicion
NCT03472508_exc_T28
Qualifier
serious
NCT03472508_exc_T29
Condition
medical conditions
NCT03472508_exc_T31
Condition
cardiac dysfunction
NCT03472508_exc_T32
Qualifier
clinically diagnosed
NCT03472508_exc_T33
Measurement
NYHA class
NCT03472508_exc_T34
Value
III and above
NCT03472508_exc_T35
Scope
NYHA class III and above
NCT03472508_exc_T36
Condition
hypertrophic obstructive cardiomyopathy
NCT03472508_exc_T30
Qualifier
clinically significant
NCT03472508_exc_T37
Condition
valvular heart disease
NCT03472508_exc_T38
Condition
acute coronary syndrome
NCT03472508_exc_T39
Temporal
within the last 3 months
NCT03472508_exc_T40
Procedure
percutaneous coronary intervention (PCI)
NCT03472508_exc_T41
Procedure
coronary artery bypass graft (CABG)
NCT03472508_exc_T42
Value
abnormal
NCT03472508_exc_T43
Temporal
pre-enrollment
NCT03472508_exc_T44
Measurement
ECG test
NCT03472508_exc_T45
Qualifier
clinically significant
NCT03472508_exc_T46
Condition
arrhythmias
NCT03472508_exc_T47
Condition
atrial flutter
NCT03472508_exc_T48
Condition
atrial fibrillation
NCT03472508_exc_T49
Condition
atrioventricular block
NCT03472508_exc_T50
Qualifier
grade II
NCT03472508_exc_T51
Qualifier
e II- atr
NCT03472508_exc_T52
Scope
grade II-III
NCT03472508_exc_T53
Scope
atrial flutter, atrial fibrillation, grade II-III atrioventricular block
NCT03472508_exc_T54
Scope
clinically significant arrhythmias
NCT03472508_exc_T55
Temporal
previous
NCT03472508_exc_T56
Condition
viral hepatitis
NCT03472508_exc_T57
Qualifier
active phase
NCT03472508_exc_T58
Value
abnormal
NCT03472508_exc_T59
Measurement
liver function test
NCT03472508_exc_T60
Temporal
pre-enrollment
NCT03472508_exc_T61
Measurement
ALT
NCT03472508_exc_T62
Measurement
AST
NCT03472508_exc_T63
Measurement
GGT
NCT03472508_exc_T64
Measurement
TBIL
NCT03472508_exc_T65
Measurement
DBIL
NCT03472508_exc_T66
Value
3 times higher than normal
NCT03472508_exc_T67
Scope
ALT, AST, GGT, TBIL, or DBIL
NCT03472508_exc_T68
Measurement
ALB
NCT03472508_exc_T69
Value
= 30g/L
NCT03472508_exc_T70
Procedure
gastrectomy
NCT03472508_exc_T71
Procedure
gastrojejunostomy
NCT03472508_exc_T72
Condition
gastrointestinal dysfunction
NCT03472508_exc_T73
Temporal
pre-enrollment
NCT03472508_exc_T74
Measurement
serum creatinine
NCT03472508_exc_T75
Value
greater than 200umol/L
NCT03472508_exc_T76
Qualifier
clinical diagnosis
NCT03472508_exc_T77
Condition
renal artery stenosis
NCT03472508_exc_T78
Procedure
kidney transplantation
NCT03472508_exc_T79
Condition
isolated kidney
NCT03472508_exc_T80
Condition
type 1 diabetes
NCT03472508_exc_T81
Qualifier
uncontrolled
NCT03472508_exc_T82
Condition
type 2 diabetes
NCT03472508_exc_T83
Measurement
fasting blood glucose
NCT03472508_exc_T84
Value
above 11.1 mmol/L
NCT03472508_exc_T85
Temporal
at pre-enrollment
NCT03472508_exc_T86
Reference_point
pre-enrollment
NCT03472508_exc_T87
Scope
fasting blood glucose above 11.1 mmol/L at pre-enrollment
NCT03472508_exc_T88
Scope
uncontrolled type 2 diabetes
NCT03472508_exc_T89
Temporal
previous
NCT03472508_exc_T90
Condition
hyperthyroidism
NCT03472508_exc_T91
Observation
failure to correct
NCT03472508_exc_T92
Condition
pulmonary heart disease
NCT03472508_exc_T93
Condition
chronic obstructive pulmonary disease
NCT03472508_exc_T94
Temporal
recent
NCT03472508_exc_T95
Condition
transient ischemic attack
NCT03472508_exc_T96
Condition
stroke
NCT03472508_exc_T97
Temporal
within the last 3 months
NCT03472508_exc_T98
Scope
transient ischemic attack or stroke
NCT03472508_exc_T99
Qualifier
peripheral
NCT03472508_exc_T100
Qualifier
severe
NCT03472508_exc_T101
Condition
autonomic dysfunction
NCT03472508_exc_T102
Scope
peripheral or severe
NCT03472508_exc_T103
Condition
al or em dysfunction, in
NCT03472508_exc_T104
Condition
nervous system dysfunction
NCT03472508_exc_T105
Scope
ALT, AST, GGT, TBIL, or DBIL 3 times higher than normal, ALB = 30g/L
NCT03472508_exc_T106
Observation
inability to express desire
NCT03472508_exc_T107
Condition
 o ndence; Ma
NCT03472508_exc_T108
Condition
alcohol dependence
NCT03472508_exc_T109
Condition
Malignancy
NCT03472508_exc_T110
Condition
malnutrition
NCT03472508_exc_T111
Condition
hematopoietic disorders
NCT03472508_exc_T112
Scope
clinically diagnosed cardiac dysfunction (NYHA class III and above), hypertrophic obstructive cardiomyopathy, clinically significant valvular heart disease, acute coronary syndrome within the last 3 months, or percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG); or abnormal pre-enrollment ECG test results with clinically significant arrhythmias (atrial flutter, atrial fibrillation, grade II-III atrioventricular block, etc.); Digestive: a previous diagnosis of various types of viral hepatitis that are still in the active phase; abnormal pre-enrollment liver function test results (ALT, AST, GGT, TBIL, or DBIL 3 times higher than normal, ALB = 30g/L); gastrectomy and/or gastrojejunostomy; gastrointestinal dysfunction; Urinary: pre-enrollment serum creatinine greater than 200umol/L; clinical diagnosis of renal artery stenosis, isolated kidney, kidney transplantation and/or other diseases; Endocrine: type 1 diabetes or uncontrolled type 2 diabetes (fasting blood glucose above 11.1 mmol/L at pre-enrollment); previous diagnosis of hyperthyroidism and failure to correct; Respiratory: pulmonary heart disease; chronic obstructive pulmonary disease; Neuropsychiatric: recent transient ischemic attack or stroke (within the last 3 months); peripheral or severe autonomic dysfunction; mental or nervous system dysfunction, inability to express desire; known drug or alcohol dependence; Malignancy, malnutrition, hematopoietic disorders
NCT03472508_exc_T113
Qualifier
Significant
NCT03472508_exc_T114
Condition
signs of abnormalities
NCT03472508_exc_T115
Measurement
laboratory tests
NCT03472508_exc_T117
Drug
folate
NCT03472508_exc_T118
Drug
B12
NCT03472508_exc_T119
Drug
B6
NCT03472508_exc_T120
Observation
refusal to stop usage
NCT03472508_exc_T121
Observation
inability
NCT03472508_exc_T122
Temporal
currently
NCT03472508_exc_T123
Scope
folate, B12, or B6
NCT03472508_exc_T124
Drug
folic acid supplements
NCT03472508_exc_T125
Multiplier
Regular usage
NCT03472508_exc_T126
Drug
compounds containing folic acid
NCT03472508_exc_T127
Temporal
in the past 3 months
NCT03472508_exc_T128
Scope
folic acid supplements or compounds containing folic acid
NCT03472508_exc_T129
Scope
 usage of fo past 3 months;
(9)Pa
NCT03472508_exc_T130
Observation
Participation in a clinical trial
NCT03472508_exc_T131
Drug
drug that has not yet been officially approved for marketing
NCT03472508_exc_T132
Temporal
within one month prior to the first visit
NCT03472508_exc_T133
Reference_point
the first visit